Kinase Inhibitors : Market Research Report

Kinase Inhibitors

Published by: BCC Research

Published: Jan. 1, 2006 - 153 Pages

INTRODUCTION: STUDY GOALS AND OBJECTIVES; REASONS FOR DOING THIS STUDY; CONTRIBUTIONS TO THE STUDY AND FOR WHOM; SCOPE AND FORMAT; METHODOLOGY; INFORMATION SOURCES; AUTHOR'S CREDENTIALS; RELATED BCC WORK CREDENTIALS; BCC ONLINE SERVICES; DISCLAIMER
SUMMARY: Summary Table: GLOBAL FORECAST OF MARKET FOR KINASE INHIBITORS BY TYPE, THROUGH 2010 ($ MILLIONS); Summary Figure:GLOBAL FORECAST OF MARKET FOR KINASE INHIBITORS BY TYPE, 2002-2010 ($ MILLION)
OVERVIEW: THE CELLULAR ROLE OF KINASES; INHIBITORS OF PROTEIN KINASES; KINASES AS ATTRACTIVE DRUG TARGETS
Table 1 ATTRACTIVE FEATURES OF PROTEIN KINASES: KINASE INHIBITORS IN CLINICAL USE AND CLINICAL TRIALS
Table 2 FDA-APPROVED* KINASE INHIBITORS
Table 3 KINASE INHIBITORS IN CLINICAL TRIALS
Table 4 NUMBER OF KINASE INHIBITORS IN CLINICAL TRIALS, BY PHASE
Table 5 COMPANIES WITH KINASE INHIBITORS IN CLINICAL TRIALS: DATABASES AND LARGE SCALE INITIATIVES
Table 6 KINASE DATABASES
TECHNOLOGY OVERVIEW: DEVELOPMENT PROCESS; TYPES OF KINASE INHIBITORS
Table 7 COMPARISON OF TYPES OF INHIBITORS: Mechanisms of Small-Molecule Inhibitors
Table 8 COMPARISON OF ATP COMPETITIVE AND NONCOMPETITIVE INHIBITORS: ATP Competitive Inhibitors; Non-ATP Competitive Inhibitors; ISSUES OF SPECIFICITY; PROTEIN STRUCTURE AND MODELING; RATIONAL DESIGN
PATENT EVALUATION
Table 9 KINASE INHIBITOR PATENTS BY TARGET MOLECULE, AUGUST 2003 TO AUGUST 2005
Table 10 KINASE INHIBITOR PATENTS BY DISEASE, AUGUST 2003 TO AUGUST 2005
Table 11 KINASE INHIBITOR PATENTS BY ASSIGNEE
Table 12 KINASE INHIBITOR PATENTS BY REGION, 2004
MARKET FOR RECEPTOR TYROSINE KINASE INHIBITORS: TOTAL MARKET SIZE
Table 13 GLOBAL FORECAST FOR RECEPTOR TYROSINE KINASE INHIBITORS MARKET BY PRODUCT, THROUGH 2010 ($ MILLIONS)
Figure 1 GLOBAL FORECAST FOR RECEPTOR TYROSINE KINASE INHIBITORS MARKET BY PRODUCT, 2002-2010 ($ MILLIONS): RECEPTOR TYROSINE KINASE BIOLOGY; INHIBITORS OF ERBB/HER FAMILY PROTEIN KINASES; EGFR INHIBITORS; GLOBAL MARKET FOR EGFR INHIBITORS
Table 14 GLOBAL MARKET FOR EGFR INHIBITORS BY REGION, THROUGH 2010 ($ MILLIONS): HER2 INHIBITORS; GLOBAL MARKET FOR HER2 INHIBITORS
Table 15 GLOBAL MARKET FOR HER2 INHIBITORS BY REGION, THROUGH 2010 ($ MILLIONS): VEGF RECEPTOR TYROSINE KINASES; FLT3 KINASE
MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITORS: TOTAL MARKET SIZE AND BACKGROUND
Table 16 GLOBAL FORECAST FOR NONRECEPTOR TYROSINE KINASE INHIBITORS MARKET BY PRODUCT, THROUGH 2010 ($ MILLIONS)
Figure 2 GLOBAL FORECAST FOR NONRECEPTOR TYROSINE KINASE INHIBITORS MARKET, 2002-2010 ($ MILLIONS): ABL KINASES
Table 17 GLOBAL FORECAST FOR ABL INHIBITORS MARKET BY REGION, THROUGH 2010 ($ MILLIONS): SRC KINASES; TARGEGEN INHIBITOR; JANUS (JAK) KINASES
MARKET FOR SERINE-THREONINE KINASE INHIBITORS: TOTAL MARKET SIZE
Table 18 GLOBAL FORECAST FOR SERINE-THREONINE KINASE INHIBITORS MARKET BY PRODUCT, THROUGH 2010 ($ MILLIONS)
Figure 3 GLOBAL FORECAST FOR SERINE-THREONINE KINASE INHIBITORS MARKET BY PRODUCT, 2002-2010 ($ MILLIONS): MTOR KINASES
Table 19 GLOBAL MARKET FOR MTOR INHIBITORS BY REGION, THROUGH 2010 ($ MILLIONS): RHO KINASES
Table 20 GLOBAL MARKET FOR RHO KINASE INHIBITORS BY REGION, THROUGH 2010 ($ MILLIONS): CYCLIN DEPENDENT KINASES; PROTEIN KINASE C (PKC); PHOSPHATIDYLINOSITOL-3-KINASE (PI3K); AURORA KINASES; MAP/MEK KINASES; JUN N-TERMINAL KINASES (JNK)
MARKET FOR KINASE INHIBITORS BY DISEASE APPLICATION: TOTAL MARKET SIZE
Table 21 GLOBAL FORECAST FOR KINASE INHIBITORS MARKET BY CURRENT APPLICATIONS, THROUGH 2010 ($ MILLION): CURRENT APPLICATIONS
Table 22 GLOBAL FORECAST FOR KINASE INHIBITORS MARKET IN CANCER TREATMENT BY PRODUCT, THROUGH 2010 ($ MILLIONS)
Table 23 WORLDWIDE MARKET FOR KINASE INHIBITORS IN IMMUNE AND INFLAMMATORY DISEASE BY PRODUCT, THROUGH 2010 (UNITS MILLIONS)
Table 24 GLOBAL FORECAST FOR KINASE INHIBITORS MARKET IN CARDIOVASCULAR DISEASE TREATMENT BY PRODUCT, THROUGH 2010 ($ MILLION): EMERGING APPLICATIONS
MAJOR COMPANIES AND MARKET SHARE: MARKET SHARES
Table 25 SALES AND MARKET SHARE OF COMPANIES INVOLVED IN KINASE INHIBITORS, 2005 ($ MILLIONS AND %)
Table 26 SALES AND MARKET SHARE OF COMPANIES INVOLVED IN TYROSINE KINASE INHIBITORS, 2005 ($ MILLIONS AND %)
Table 27 SALES AND MARKET SHARE OF COMPANIES INVOLVED IN SERINE THREONINE KINASE INHIBITORS, 2005 ($ MILLIONS AND %)
COMPANY PROFILES: AMBIT BIOSCIENCES; AMGEN; ARIAD PHARMACEUTICALS; ASTRAZENECA; BOEHRINGER INGELHEIM; CEPHALON INC.; CEPTYR, INC.; CGI PHARMACEUTICALS, INC; CHIRON, INC.; CYCLACEL LIMITED; EXELIXIS; GENENTECH INC.; GLAXOSMITHKLINE; GPC BIOTECH AG; IMCLONE SYSTEMS; KAI PHARMACEUTICALS; KÉMIA; KINEXUS BIOINFORMATICS CORP.; MERCK AND CO.; MILLENIUM PHARMACEUTICALS; MYRIAD GENETICS, INC.; NOVARTIS; PFIZER INC.; ROCHE (F. HOFFMANN-LA ROCHE LTD); SANOFI-AVENTIS; SCIOS; TARGEGEN; VERTEX; WYETH-AYERST
INTERNATIONAL ASPECTS AND REGULATORY ISSUES: MARKET BY REGION
Table 28 GLOBAL FORECAST FOR KINASE INHIBITORS MARKET BY REGION, THROUGH 2010 ($ MILLIONS)
Figure 4 REGIONAL SHARE OF GLOBAL MARKET FOR KINASE INHIBITORS, 2005 AND 2010 (%)
FUTURE DIRECTIONS: SPECIFICITY AND COMPLEXITY; RESISTANCE; KINASE ACTIVATORS; DEVELOPMENTS IN ENABLING TECHNOLOGIES

Abstract

INTRODUCTION

Human protein kinases are intriguing drug targets, in part because they regulate a wide variety of signaling pathways and include over 500 distinct protein molecules. Synthetic inhibitors of protein kinases include small molecules that may be easily administered as oral therapeutic compounds. These inhibitors can rapidly and often specifically alter the activation state of a target kinase. They further have significant potential in the clinical treatment of major diseases including cancer, heart disease, inflammatory disorders, diabetes, macular degeneration, and neurological disorders.

This BCC study determines the current status of the kinase inhibitor industry and assesses its growth potential. Only a handful such therapeutics have entered clinical use as of 2005. For each, BCC examined the drug development process, major challenges and achievements and where applicable, the projected market for each of these drugs through 2010.

Of particular interest are up-and-coming kinase inhibitors in clinical trials and preclinical development. Leading candidates are identified in each kinase inhibitor class by molecular target and by disease application. The result is a comprehensive analysis of the current market and its future direction.

SCOPE OF STUDY

The report contains:

A thorough review of the technologies employed in the kinase inhibitor
Analysis of the evidence of efficacy and technical limitations of each kinase inhibitor type in clinical use
Analysis of the current market status and growth forecasts through 2010 for each kinase inhibitor
Examination of the potential for additional novel applications
Discussion of the role of government regulations, recent patents and factors affecting the industry worldwide
Analysis of how the development of new kinase inhibitors is translating into new medical therapies for specific disease

METHODOLOGY

The market assessments provided have been assembled based on publicly available information from January 2002 up to and including August 2005. The base year for this report is 2005 and forecast data are provided through 2009. In cases where data for 2005 were not available, figures were extrapolated from 2004 statistics, half-year figures for 2005 and historical trends between 2001 and 2004. Market figures are based on current dollars and inflation is not computed into the projection figures. Interviews were also used to adjust market size estimates, as well as to formulate market projections.

The field of kinase inhibitor development is still immature and the reader is cautioned to use the report data as a guide to assess trends, developments and challenges that the industry faces.

INFORMATION SOURCES

The information contained in this report has been assembled from primary and secondary data. Primary research was conducted via telephone interviews with selected industry professionals, research scientists, and laboratory heads to discover the most recent developments in their fields of interest. Secondary data was collected via a comprehensive search of the scientific, peer-reviewed literature, clinical trial reports and databases, industry trade media, company websites, annual reports and industry press releases.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

2/14/2012 - 32

Kinase Inhibitors

Table of Contents

Abstract